Apply for funding

Call for Expressions of Interest (EOI)
Now Open!

ACH4 eOI - Grant Round 2027:
Friday 9th October - friday 13th november, 2026

view EOI supporting materials on this page.

any questions: please contact Jo Reidy (02) 9842 9175
joanne.reidy@wimr.org.au

Grant Application Outline

Over the past 23 years, ACH4 has supported translational research in the areas of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) and more recently human T-lymphotropic virus type-1 (HTLV-1). In 2027, ACH4 will continue to support translational research into these four viral infections.

ACH4 is seeking expressions of interest (EOI) in applied research from qualified scientists to fund research projects focused on: i) development of vaccine candidates for HIV, HBV subtypes, HCV or HTLV-1; ii) development of prevention strategies, including HIV microbicides and pre-exposure prophylaxis (PrEP); iii) cure and treatment interventions for HIV, HBV, or HTLV-1, including immunotherapy iv) novel diagnostics and prognostics for HIV, HBV, HCV, HTLV-1 or hepatitis B/C/HIV/HTLV-1 co-infection; v) molecular tools for tracking epidemics caused by these viruses; and vi) development of new tests for supporting vaccine and antiviral trials for these four viruses. Basic research is not eligible for funding, nor are projects focused on developing new direct-acting antivirals for HCV.

Research projects based on clinical data and specimens from patients with HIV, HCV and HBV stored by the Immunovirology Research Network (IVRN) are encouraged.

The grants are intended to complement and translate basic research projects in the virology and immunology of HIV, HBV, HCV and HTLV-1 that are commonly funded by other granting bodies such as NHMRC. The ACH4 grants are not intended for the basic research itself. A few awards will be available for seed funding of applications that are viewed by the Scientific Advisory Committee (SAC) to be exciting & innovative ideas that have the potential for longer-term translation.

Funding is available from 1 January 2027 to 30 October 2027 for grants up to $50,000.

Eligibility: Applications are invited from Australian investigators (citizens or permanent residents), whether employed at an Australian university, hospital, research institute or other similar institution conducting research in Australia. Investigators who are currently designated as Chief Investigator A (CIA) on another grant application funded through the Australian Government Department of Health G05055 Blood Borne Viruses (BBV) and Sexually Transmissible Infections (STI) Research Program are not eligible to apply in this capacity.

To ensure broad participation and equitable access to funding opportunities, each eligible CIA may submit only one application under this funding round. Collaborative approaches are strongly encouraged and applications from national multidisciplinary and multi-institutional collaborative groups are particularly welcomed.

Applications must be submitted by the Administering Institute or University Research Officer via the ACH4 online application portal: https://ach4.org.au/apply/ if you have any issues with the portal please contact: joanne.reidy@wimr.org.au. ACH4 grants will be awarded to the administering organisation through which the CI-A submits their application. All awards will be governed by a participant agreement (between the participant organisation and The Westmead Institute for Medical Research representing ACH4).

All administering organisations awarded a grant will be required to enter such an agreement.

Guidelines explaining further details & eligibility criteria of this funding is available under EOI materials or please contact:
Joanne Reidy – Administration Officer, ACH4
The Westmead Institute for Medical Research

PO Box 412, Westmead NSW 2145 Phone: (02) 9842 9175 /

Email: joanne.reidy@wimr.org.au 

Expressions of Interest close at 5:00 pm AEDT on Friday 13 November 2026
Areas of Research: HIV, Hepatitis B, Hepatitis C and HTLV-1

Apply Here

EOI Materials

EOI FAQs

ACH4 applications must be submitted by the Administering Institute or University Research Office via the ACH4 online application portal: https://ach4.org.au/apply/

Applications submitted directly by individual applicants to the ACH4 Administration Officer will not be accepted. Applicants should work with their institution’s Research Office to ensure all required approvals are obtained prior to submission.

If you experience any issues accessing or using the online portal, please contact joanne.reidy@wimr.org.au for assistance.

The Chief Investigator A (CI-A) must be an Australian citizen or permanent resident, be based in Australia and administer the grant through an eligible Australian institution. Overseas-based investigators and international collaborators may be included as co-investigators and ACH4 encourages collaborative and multidisciplinary research teams, including appropriate international partnerships. However, all ACH4 grant funding must be administered by an Australian institution and expended within Australia. The CI-A must be substantially based in Australia for the duration of the grant i.e. for at least 80% of the funding period.

No. Individuals currently enrolled in a PhD program are not eligible to apply for ACH4 funding as a Chief Investigator A (CI-A). However, PhD students may be included as a co-investigator where their involvement is critical to the successful completion of the proposed research.

Yes. While PhD students cannot apply as a CI-A, they may be named as a co-investigator if they play an important role in delivering the proposed project.

No. Postdoctoral researchers who are within three years of completing their PhD are considered to be in a training position for the purposes of these awards and are not eligible to apply as CI-A.

Refer to the ACH4 Application Guidelines

Let ACH4 be your partner

Skip to content